Background

Stent thrombosis (ST) is a serious complication of percutaneous coronary stenting associated with significant mortality and morbidity. ST is believed to vary in clinical setting depending on the type of stent, discontinuation of dual-antiplatelet therapy (DAPT) and concurrent proton pump inhibitors (PPI) use. We aim to describe the characteristics of patients presenting with ST.

Methods

All patients presenting to our two centers for primary angioplasty (PAMI) having definite ST as per ARC definition over a 45-month period were identified and included in the analysis. Acute ST (AST) was defined as ST occurring <24 h of stent deployment; subacute (SAT) as 24 h–30 days; late ST (LAST) as 30–360 days and very late ST (VLAST) as >1 year.

Methods

All patients presenting to our two centers for primary angioplasty (PAMI) having definite ST as per ARC definition over a 45-month period were identified and included in the analysis. Acute ST (AST) was defined as ST occurring <24 h of stent deployment; subacute (SAT) as 24 h–30 days; late ST (LAST) as 30–360 days and very late ST (VLAST) as >1 year.

Only gold members can continue reading. Log In or Register to continue

Share this:

• Click to share on Twitter (Opens in new window)
• Click to share on Facebook (Opens in new window)

Related

Related posts:

1. Coronary stenting with MGuard: extended follow-up of first human trial
2. Understanding the impact of drug-eluting stent on vascular function and the nitric oxide pathway genes using a pig coronary artery stent implantation model
3. Statin improves outcome of patients presenting with first acute myocardial infarction
4. Risk factors and impact of contrast left ventriculogram on incidence of contrast-induced nephropathy: is left ventriculogram really necessary?

Stay updated, free articles. Join our Telegram channel

Join

Full access? Get Clinical Tree